Get started
Author

Holly M. Astley

Observed names: H.M. Astley, Holly Astley
OpenAlex ID: A5026543846
Arabidopsis uses two gluconeogenic gateways for organic acids to fuel seedling establishment
2015 · Peter J. Eastmond, Holly M. Astley, et al. · Nature Communications · 142
PDF
Isocitrate Dehydrogenase (IDH) Mutations Promote a Reversible ZEB1/MicroRNA (miR)-200-dependent Epithelial-Mesenchymal Transition (EMT)
2012 · Alexandra R. Grassian, Fallon Lin, et al. · Journal of Biological Chemistry · 122
PDF
C4acid decarboxylases required for C4photosynthesis are active in the mid-vein of the C3speciesArabidopsis thaliana, and are important in sugar and amino acid metabolism
2009 · Naomi J. Brown, Ben G. Palmer, et al. · The Plant Journal · 116
PDF
Synthetic Lethal Targeting of ARID1A -Mutant Ovarian Clear Cell Tumors with Dasatinib
2016 · Rowan E. Miller, Rachel Brough, et al. · Molecular Cancer Therapeutics · 89
Photosynthesis in cells around veins of the C3 plant Arabidopsis thaliana is important for both the shikimate pathway and leaf senescence as well as contributing to plant fitness
2009 · Sophie H. Janacek, Sandra Trenkamp, et al. · The Plant Journal · 49
The pyruvate, orthophosphate dikinase regulatory proteins of Arabidopsis are both bifunctional and interact with the catalytic and nucleotide‐binding domains of pyruvate, orthophosphate dikinase
2011 · Holly M. Astley, Kate Parsley, et al. · The Plant Journal · 27
Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling
2016 · Chia-Wen Hsu, Ruili Huang, et al. · Oncotarget · 25
Supplementary Figures from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
PDF
Supplementary Table 12 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 3 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 11 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 2 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Figure legends and methods from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 10 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 1 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Data from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 8 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 6 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 7 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 1 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 4 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 9 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 5 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Supplementary Table 5 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
2023 · Rowan E. Miller, Rachel Brough, et al.
Abstract 3136: X-MAN™ isogenic DualXenoTM models with KRAS mutation predicts the effect of anti-EGFR agents
2014 · Yanmei Sun, Songling Zhang, et al. · Cancer Research
Works count: 32
Citation count: 570
H-index: 7
I10-index: 7
Year
Topic
Type